Sinopharm Group Co. Ltd. (SHTDY)
USD 11.73
(0.22%)
USD 11.73
(0.22%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.89 Billion CNY | -1.67% |
| 2022 | 26.24 Billion CNY | 7.24% |
| 2021 | 24.68 Billion CNY | 7.87% |
| 2020 | 22.61 Billion CNY | 9.24% |
| 2019 | 20.31 Billion CNY | 26.19% |
| 2018 | 16.67 Billion CNY | 34.51% |
| 2017 | 13.43 Billion CNY | 15.4% |
| 2016 | 12.03 Billion CNY | 11.59% |
| 2015 | 10.43 Billion CNY | 16.84% |
| 2014 | 8.96 Billion CNY | 27.69% |
| 2013 | 7.02 Billion CNY | 24.18% |
| 2012 | 5.9 Billion CNY | 24.53% |
| 2011 | 4.43 Billion CNY | 48.38% |
| 2010 | 3.04 Billion CNY | 51.32% |
| 2009 | 2.01 Billion CNY | 32.82% |
| 2008 | 1.51 Billion CNY | 37.05% |
| 2007 | 1.1 Billion CNY | 86.79% |
| 2006 | 592.22 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.9 Billion CNY | -52.85% |
| 2024 Q2 | 5.56 Billion CNY | 42.47% |
| 2023 Q3 | 4.3 Billion CNY | -32.21% |
| 2023 FY | - CNY | -1.67% |
| 2023 Q1 | 4.51 Billion CNY | -46.8% |
| 2023 Q4 | 8.28 Billion CNY | 92.31% |
| 2023 Q2 | 6.35 Billion CNY | 40.7% |
| 2022 Q4 | 8.49 Billion CNY | 70.92% |
| 2022 Q1 | 4.23 Billion CNY | -40.74% |
| 2022 FY | - CNY | 7.24% |
| 2022 Q2 | 6.27 Billion CNY | 48.03% |
| 2022 Q3 | 4.96 Billion CNY | -20.8% |
| 2021 FY | - CNY | 7.87% |
| 2021 Q3 | 5.68 Billion CNY | -10.51% |
| 2021 Q2 | 6.35 Billion CNY | 73.59% |
| 2021 Q4 | 7.15 Billion CNY | 25.81% |
| 2021 Q1 | 3.65 Billion CNY | -44.2% |
| 2020 Q2 | 5.43 Billion CNY | 82.67% |
| 2020 Q4 | 6.55 Billion CNY | 12.3% |
| 2020 Q3 | 5.83 Billion CNY | 7.34% |
| 2020 Q1 | 2.97 Billion CNY | -49.63% |
| 2020 FY | - CNY | 9.24% |
| 2019 Q3 | 4.69 Billion CNY | -14.83% |
| 2019 FY | - CNY | 26.19% |
| 2019 Q1 | 3.48 Billion CNY | -29.78% |
| 2019 Q2 | 5.51 Billion CNY | 58.35% |
| 2019 Q4 | 5.91 Billion CNY | 25.89% |
| 2018 Q2 | 4.86 Billion CNY | 66.2% |
| 2018 FY | - CNY | 34.51% |
| 2018 Q1 | 2.92 Billion CNY | -25.95% |
| 2018 Q3 | 3.86 Billion CNY | -20.51% |
| 2018 Q4 | 4.95 Billion CNY | 28.18% |
| 2017 FY | - CNY | 15.4% |
| 2017 Q3 | 3.95 Billion CNY | 24.4% |
| 2017 Q4 | 3.95 Billion CNY | 0.0% |
| 2017 Q1 | 3.17 Billion CNY | 17.01% |
| 2017 Q2 | 3.17 Billion CNY | 0.0% |
| 2016 Q1 | 2.67 Billion CNY | 5.9% |
| 2016 Q4 | 2.71 Billion CNY | 0.0% |
| 2016 Q3 | 2.71 Billion CNY | -10.14% |
| 2016 Q2 | 3.02 Billion CNY | 12.88% |
| 2016 FY | - CNY | 11.59% |
| 2015 Q2 | 2.64 Billion CNY | 11.06% |
| 2015 Q3 | 2.52 Billion CNY | -4.45% |
| 2015 Q4 | 2.52 Billion CNY | 0.0% |
| 2015 FY | - CNY | 16.84% |
| 2015 Q1 | 2.38 Billion CNY | 10.06% |
| 2014 FY | - CNY | 27.69% |
| 2014 Q4 | 2.16 Billion CNY | 0.0% |
| 2014 Q3 | 2.16 Billion CNY | 1.19% |
| 2014 Q2 | 2.13 Billion CNY | 0.0% |
| 2014 Q1 | 2.13 Billion CNY | 26.19% |
| 2013 Q1 | 1.65 Billion CNY | 0.0% |
| 2013 FY | - CNY | 24.18% |
| 2013 Q2 | 1.65 Billion CNY | 0.0% |
| 2013 Q4 | 1.69 Billion CNY | 0.0% |
| 2013 Q3 | 1.69 Billion CNY | 2.46% |
| 2012 FY | - CNY | 24.53% |
| 2011 FY | - CNY | 48.38% |
| 2010 FY | - CNY | 51.32% |
| 2009 FY | - CNY | 32.82% |
| 2008 FY | - CNY | 37.05% |
| 2007 FY | - CNY | 86.79% |
| 2006 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| China Medicine Corporation | 13.27 Million USD | -202476.297% |
| DH Enchantment Inc. | -145.23 Thousand USD | 18521736.026% |
| Exlites Holdings International, Inc. | -90.49 Thousand USD | 29725020.16% |
| Itonis, Inc. | -38.31 Thousand USD | 70214070.243% |
| One Step Vending Corp. | -26.55 Thousand USD | 101306864.086% |
| MediPal Holdings Corporation | 431.52 Million USD | -6133.497% |
| PD-Rx Pharmaceuticals, Inc. | -51.41 Thousand USD | 52313392.752% |
| Pharmagen, Inc. | -2.89 Million USD | 929713.218% |
| Suzuken Co., Ltd. | 340.78 Million USD | -7793.297% |